Dr Thomas Lamb
Snake bite coordinator
Thomas Lamb is a project coordinator for antivenom research at MOCRU and the 1st Hamish Ogston Foundation Fellow. His prior clinical experience with snake-bite envenoming in India, Bangladesh and UK has resulted in a desire to improve antivenom availability and affordability to those who need it most in a timely manner.
Snake bite in Myanmar is the leading cause of acute kidney injury requiring dialysis and is estimated to cause 1,250 death/year. The principal objective of this work is to conduct a dose-finding study of a novel lyophilized Daboia siamensis antivenom produced in Myanmar. The optimal dose will seek to reverse the effects of venom in a single dose whilst limiting the incidence of severe adverse reactions. In addition to the dose-finding trial, we plan to investigate snake-bite diagnostics including the 20-minute whole blood clotting test, perform a pharmacokinetic assessment of venom in humans and describe the Daboia siamensis envenoming sequelae.
Moderate-to-severe Vipera berus envenoming requiring ViperaTAb antivenom therapy in the UK
Lamb T. et al, (2021), CLINICAL TOXICOLOGY
A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: Application to a dose-finding trial for a novel Russell’s viper antivenom in Myanmar
Watson JA. et al, (2020), PLOS Neglected Tropical Diseases, 14, e0008109 - e0008109
A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: application to a dose-finding trial for a novel Russell’s viper antivenom in Myanmar
Watson JA. et al, (2020)
Short-term glucose dysregulation following acute poisoning with organophosphorus insecticides but not herbicides, carbamate or pyrethroid insecticides in South Asia.
Gifford RM. et al, (2019), Clinical toxicology (Philadelphia, Pa.), 57, 254 - 264
Severe Systemic Envenomation Following Vipera berus Bite Managed with ViperaTAb Antivenom.
Hamilton J. et al, (2019), Wilderness Environ Med, 30, 56 - 58